Rational ligand-based virtual screening and structure-activity relationship studies in the ligand-binding domain of the glucocorticoid receptor-α

Future Medicinal Chemistry

Volumn 1, Issue 3, 2009, Pages 483-499

  Onnis, Valeria ^a   Kinsella, Gemma K ^a   Carta, Giorgio ^a   Fayne, Darren ^a   Lloyd, David G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO PYRAZOLE 2,6 DICHLORO ETHYL BENZAMIDE; DEACYLCORTIVAZOL; DEXAMETHASONE; FLUTICASONE FUROATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR ANTAGONIST; GSK 866; HYDROCORTISONE; MIFEPRISTONE; STEROID; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG SCREENING; DRUG STRUCTURE; EDEMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MUSCLE WEAKNESS; MYOPATHY; NEUROSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIDE EFFECT; ULCER; WEIGHT GAIN;

COMPUTER SIMULATION; DRUG DESIGN; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUCOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77951115349     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.39     Document Type: Review

References (86)

1. Coghlan MJ, Elmore SW, Kym PR, Kort ME. The pursuit of differentiated ligands for the glucocorticoid receptor. Curr. Top. Med. Chem. 3(14), 1617-1635 (2003).
2. Kumar R,Thompson EB. Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Mol. Endocrinol. 17(1), 1-10 (2003).
3. Bledsoe RK, Montana VG, Stanley TB et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 110(1), 93-105 (2002).
4. Sack FU, Reidenbach B, Dollner R, Schledt A, Gebhard MM, Hagl S. Influence of steroids on microvascular perfusion injury of the bowel induced by extracorporeal circulation. Ann. Thorac. Surg. 72(4), 1321-1326 (2001).
5. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature. 393(6683), 392-396 (1998).
6. Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc. Am. Thorac. Soc. 1(3), 239-246 (2004).
7. Gaffo A, Saag KG, Curtis, JR Treatment of rheumatoid arthritis. Am. J. Health Syst. Pharm. 63(24), 2451-2465 (2006).
8. Ito K, Getting SJ, Charron CE. Mode of glucocorticoid actions in airway disease. Scientific World Journal 6, 1750-1769 (2006).
9. Gladman DD, Urowitz MB, Doris F et al. Glucocorticoid receptors in systemic lupus erythematosus. J. Rheumatol. 18(5), 681-684 (1991).
10. Rebuffat AG, Tam S, Nawrocki AR et al. The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol. Cell. Endocrinol. 214(1-2), 27-37 (2004).
11. Suino-Powell K, Xu Y, Zhang C et al. Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Mol. Cell. Biol. 28(6), 1915-1923 (2008).
12. Salter M, Biggadike K, Matthews JL et al. Pharmacological properties of the enhancedaffinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am. J. Physiol. Lung Cell Mol. Physiol. 293(3), L660-L667 (2007).
13. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96(1), 23-43 (2002).
14. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu. Rev. Med. 48, 129-156 (1997).
15. Laue L, Gallucci W, Loriaux DL, Udelsman R, Chrousos GP. The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. J. Clin. Endocrinol. Metab. 67(3), 602-606 (1988).
16. Nieman LK, Chrousos GP, Kellner C et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 61(3), 536-540 (1985).
17. van den Berg DT, de Kloet ER, van Dijken HH, de Jong W. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure. Endocrinology 126(1), 118-124 (1990).
18. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21(5), 516-521 (2001).
19. Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J. Psychiatry Neurosci. 18(5), 209-213 (1993).
20. Kling MA, Whitfield HJ Jr, Brandt HA et al. Effects of glucocorticoid antagonism with RU 486 on pituitary-adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion. Psychopharmacol. Bull. 25(3), 466-472 (1989).
21. Huscher D, Thiele K, Gromnica-Ihle E et al. Dose-related patterns of glucocorticoidinduced side effects. Ann. Rheum. Dis. DOI: 10.1136/ard.2008. 092163 (2008) (Epub ahead of print).
22. Kauppi B, Jakob C, Färnegårdh M et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278(25), 22748-22754 (2003).
23. Biggadike K, Bledsoe RK, Hassell AM et al. X-ray crystal structure of the novel enhancedaffinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J. Med. Chem. 51(12), 3349-3352 (2008).
24. Madauss KP, Bledsoe RK, Mclay I et al. The first x-ray crystal structure of the glucocorticoid receptor bound to a nonsteroidal agonist. Bioorg. Med. Chem. Lett. 18(23), 6097-6099 (2008).
25. Onnis V, Kinsella GK, Carta G, Fayne F, Lloyd DG. Rational structure based drug design and optimisation in the ligand binding domain of the glucocorticoid receptor ? Future Med. Chem. 1(2), 345-359 (2008).
26. MOE, (Molecular Operating Environment). Chemical Computing Group: Montreal QC.
27. Buttgereit F, da Silva JA, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 61(8), 718-722 (2002).
28. Encio IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J. Biol. Chem. 266(11), 7182-7188 (1991).
29. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55(7), 603-613 (2000).
30. Schäcke H, Schottelius A, Döcke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 101(1), 227-232 (2004).
31. Buckbinder L, Robinson RP. The glucocorticoid receptor: molecular mechanism and new therapeutic opportunities. Curr. Drug Targets Inflamm. Allergy. 1(2), 127-136 (2002).
32. Mohler ML, He V, Wu Z, Hong SS, Miller DD. Dissociated non-steroidal glucocorticoids receptor: tuning out untoward effects. Expert Opin. 17(1), 37-58 (2007).
33. McMaster A, Ray DW. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp. Physiol. 92(2), 299-309 (2007).
34. Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 32, 335-373 (2003).
35. Klebe G, Abraham U. Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J. Comput. Aided Mol. Des. 13(1), 1-10 (1999).
36. Gubernator K, Böhm H-J. Structure-Based Ligand Design. Mannhold R, Kubinyi H, Timmerman H (Eds). Wiley-VCH, Weinheim, Germany (1998).
37. Jorgensen WL. The many roles of computation in drug discovery. Science 303(5665), 1813-1818 (2004).
38. Bissantz C, Folkers G, Rognan D. Proteinbased virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 43(25), 4759-4767 (2000).
39. Blin N, Federici C, Koscielniak T, Strosberg AD. Predictive quantitative structure-activity relationships (QSAR) analysis of 3-adrenergic ligands. Drug. Des. Discov. 12(4), 297-311 (1995).
40. Muir RM, Fujita T, Hansch C. Structure-activity relationship in the auxin activity of mono-substituted phenylacetic acids. Plant Physiol. 42(11), 1519-1526 (1967).
41. Hoffman BT, Kopajtic T, Katz JL, Newman AH. 2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors. J. Med. Chem. 43(22), 4151-4159 (2000).
42. Netzeva T, Doytchinova I, Natcheva R. 2D and 3D QSAR analysis of some valproic acid metabolites and analogues as anticonvulsant agents. Pharm. Res. 17(6), 727-732 (2000).
43. Hunt PA. QSAR using 2D descriptors and TRIPOS' SIMCA. J. Comput. Aided Mol. Des. 13(5), 453-467 (1999).
44. Good AC, Peterson SJ, Richards WG. QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods. J. Med. Chem. 36(20), 2929-2937 (1993).
45. Makhija MT, Kulkarni VM. 3D-QSAR and molecular modeling of HIV-1 integrase inhibitors. J. Comput. Aided Mol. Des. 16(3), 181-200 (2002).
46. Liao C, Xie A, Zhou J, Shi L, Li Z, Lu XP. 3D QSAR studies on peroxisome proliferatoractivated receptor gamma agonists using CoMFA and CoMSIA. J. Mol. Model 10(3), 165-177 (2004).
47. Carta G, Onnis V, Knox AJ, Fayne D, Lloyd DG. Permuting input for more effective sampling of 3D conformer space. J. Comput. Aided Mol. Des. 20(3), 179-190 (2006).
48. CORINA 3.6., distributed by Molecular Networks GmbH.
49. RUBICON, distributed by Daylight Chemical Informations Systems Inc.
50. OMEGA 1.8.1., distributed by Openeye Scientific Software.
51. Gund P. Three-dimensional pharmacophoric pattern searching Prog. Mol. Subcell. Biol. 5, 117-143 (1977).
52. Morgan BP, Swick AG, Hargrove DM et al. Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J. Med. Chem. 45(12), 2417-2424 (2002).
53. Poupaert JH, Lambert DM, Vamecq J, Abul-Hajj YJ. Molecular modeling studies on 11-aminoethoxyphenyl and 7-aminoethoxyphenyl estradiols. Evidence suggesting a common hydrophobic pocket in estrogen recetpor. Bioorg. Med. Chem. Lett. 5(8), 839-842 (1995).
54. Coghlan MJ, Kym PR, Elmore SW et al. Synthesis and characterization of nonsteroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity. J. Med. Chem. 44(18), 2879-2885 (2001).
55. Takahashi H, Bekkali Y, Capolino AJ et al. Discovery and SAR study of novel dihydroquinoline-containing glucocorticoid receptor agonists. Bioorg. Med. Chem. Lett. 17(18), 5091-5095 (2007).
56. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 464(1-2), 9-13 (1999).
57. Ali A, Thompson CF, Balkovec JM et al. Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity. J. Med. Chem. 47(10), 2441-2452 (2004).
58. Hirschmann R, Steinberg NG, Schoenewaldt EF, Paleveda WJ, Tishler M. Synthesis of pregn-4-eno(3,2-C)pyrazoles related to 9-α-fluoro-16-α- methylcortisol. J. Med. Chem. 7, 352-355 (1964).
59. Resche-Rigon M, Gronemeyer H. Therapeutic potential of selective modulators of nuclear receptor action. Curr. Opin. Chem. Biol. 2(4), 501-507 (1998).
60. Smith CJ, Ali A, Balkovec JM et al. Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity. Bioorg. Med. Chem. Lett. 15(11), 2926-2931 (2005).
61. Thompson CF, Quraishi N, Ali A et al. Novel glucocorticoids containing a 6,5-bicyclic core fused to a pyrazole ring: synthesis, in vitro profile, molecular modeling studies, and in vivo experiments. Bioorg. Med. Chem. Lett. 17(12), 3354-3361 (2007).
62. Crippen GM, Havel TF. Distance Geometry and Molecular Conformation. Research Studies Press, Wiley, NY, USA (1988).
63. Clark RD, Ray NC, Williams K et al. 1H-Pyrazolo[3,4-g]hexahydro- isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg. Med. Chem. Lett. 18(4), 1312-1317 (2008).
64. Betageri R, Zhang Y, Zindell RM et al. Trifluoromethyl group as a pharmacophore: effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. Bioorg. Med. Chem. Lett. 15(21), 4761-4769 (2005).
65. Regan J, Lee TW, Zindell RM et al. Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonists. J. Med. Chem. 49(26), 7887-7896 (2006).
66. Coghlan MJ, Elmore SW, Kym PR, Kort ME. Selective glucocorticoid receptor modulators. In: Annual Reports in Medicinal Chemistry. Doherty AM (Ed.). Academic Press, NY, USA (2002).
67. Thompson CF, Quraishi N, Ali A et al. Novel heterocyclic glucocorticoids: in vitro profile and in vivo efficacy. Bioorg. Med. Chem. Lett. 15(8), 2163-2167 (2005).
68. Katchen B, Buxbaum S. Disposition of a new, nonsteroid, antiandrogen, α α α -trifluoro-2- methyl-4́-nitro-m-propionotoluidide (flutamide), in men following a single oral 200 mg dose. J. Clin. Endocrinol. Metab. 41(2), 373-379 (1975).
69. Tucker H, Crook JW, Chesterson GJ. Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J. Med. Chem. 31(5), 954-959 (1988).
70. Barker M, Clackers M, Demaine DA et al. Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method. J. Med. Chem. 48(14), 4507-4510 (2005).
71. Roach SL, Higuchi RI, Adams ME et al. Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4- tetrahydroquinolines. Bioorg. Med. Chem. Lett. 18(12), 3504-3508 (2008).
72. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 347(Pt 2), 321-337 (2000).
73. Lewis DF, Ioannides C, Parke DV, Schulte-Hermann R. Quantitative structure- activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis. J. Steroid Biochem. Mol. Biol. 74(4), 179-185 (2000).
74. Lewis DFV, Ogg MS, Goldfarb PS, Gibson GG. Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERα) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J. Steroid Biochem. Mol. Biol. 82(2-3), 195-199 (2002).
75. Genetic Computer Group an Oxford Molecular Company: 575 Science Drive, Madison Wisconsin 53711, USA.
76. Ogg MS. In vitro assessment of the regulation of the human CYP3A4 gene. Ph.D. Thesis, School of Biomedical and Life Sciences, University of Surrey, UK (1998).
77. Pallas. CompuDrug Chemistry Ltd, Budapest, Hungary.
78. Hammer S, Spika I, Sippl W et al. Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. Steroids 68(4), 329-339 (2003).
79. Buchwald P. General linearized biexponential model for QSAR data showing bilinear-type distribution. J Pharm. Sci. 94(11), 2355-2379 (2005).
80. Spreafico M, Ernst B, Lill MA, Smiesko M, Vedani A. Mixed-model QSAR at the glucocorticoid receptor: predicting the binding mode and affinity of psychotropic drugs. ChemMedChem 4(1), 100-109 (2008).
81. Vedani A, Hutha DW. An algorithm for the systematic solvation of proteins based on the directionality of hydrogen bonds. J. Am. Chem. Soc. 112, 4759-4767 (1990).
82. Vedani A, Zumstein M, Lill MA, Ernst B. Simulating α/ βselectivity at the human thyroid hormone receptor: consensus scoring using multidimensional QSAR. ChemMedChem 2(1), 78-87 (2007).
83. Vedani A, Spreafico M, Peristera O, Dobler M, Smiesko M. VirtualToxLab-in silico prediction of the endocrine-disrupting potential of drugs and chemicals. Chimia (Aarau) 62, 322-328 (2008).
84. Ray NC, Clark RD, Clark DE et al. Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. Bioorg. Med. Chem. Lett. 17(17), 4901-4905 (2007).
85. Mohamadi F, Richards MGJ, Guida WC et al. MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11, 440 (1990).
86. Ray NC, Clark RD, Clark DE et al. Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. Bioorg. Med. Chem. Lett. 17(17), 4901-4905 (2007).